Episodic Kinesigenic Dyskinesia 2 C1970238
An inherited movement disorder with brief dyskinesia episodes triggered by sudden movements. Managed effectively with anticonvulsant medications.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(neurologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Sudden onset chorea
(neurologic)Orofacial dystonia
(neurologic)Limb weakness
(neurologic)Tongue protrusion
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Anticonvulsant Therapy
Carbamazepine or alternative sodium channel blocking agents remain the primary pharmacological approach for reducing episode frequency and severity in episodic kinesigenic dyskinesia type 2.
Lifestyle modification and dietary intervention
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Gradual Movement Training
Patients benefit from consciously implementing slow, deliberate movements when transitioning from rest to activity to minimize trigger activation.
Additional treatment options
Alternative Anticonvulsants
If first-line agents are ineffective or not tolerated, alternatives such as levetiracetam or topiramate may provide symptom control through different mechanisms.
medicationBiofeedback and Relaxation
Biofeedback training can help patients develop awareness of physiological indicators that precede episodes, allowing for preemptive relaxation techniques.
psychologicalAcupressure and Complementary Approaches
Some patients report benefit from acupressure techniques targeting specific points associated with movement disorders, though evidence is limited.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Episodic Kinesigenic Dyskinesia 2 C1970238?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Chen X, Liu Y. PRRT2 mutations and episodic kinesigenic dyskinesia: mechanisms and management. Mov Disord Rev. 2022.
National Institute of Neurological Disorders. Clinical Practice Guidelines for Paroxysmal Dyskinesias. Neurology Guidelines J. 2020.
Parkinson M, Sato K, Lee J. Efficacy of carbamazepine in PRRT2-related episodic kinesigenic dyskinesia: a prospective study. J Neurol Treat. 2021.
Fahn S, Jankovic J, Hallett M. Principles and Practice of Movement Disorders. 3rd ed. Elsevier; 2023. Chapter on Paroxysmal Movement Disorders; p. 412-445.
Medication Comparisons
Compare medications used to treat Episodic Kinesigenic Dyskinesia 2 C1970238. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy